Cyclopharm Ltd
ASX:CYC
Cyclopharm Ltd
Income from Continuing Operations
Cyclopharm Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
C
|
Cyclopharm Ltd
ASX:CYC
|
Income from Continuing Operations
-AU$4.7m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-166%
|
CAGR 10-Years
7%
|
Neurotech International Ltd
ASX:NTI
|
Income from Continuing Operations
-AU$5m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
ImpediMed Ltd
ASX:IPD
|
Income from Continuing Operations
-AU$19.4m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-11%
|
|
Cochlear Ltd
ASX:COH
|
Income from Continuing Operations
AU$350.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
6%
|
CAGR 10-Years
17%
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Income from Continuing Operations
-AU$5.4m
|
CAGR 3-Years
-61%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-11%
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Income from Continuing Operations
-AU$3.9m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
See Also
What is Cyclopharm Ltd's Income from Continuing Operations?
Income from Continuing Operations
-4.7m
AUD
Based on the financial report for Dec 31, 2023, Cyclopharm Ltd's Income from Continuing Operations amounts to -4.7m AUD.
What is Cyclopharm Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
7%
Over the last year, the Income from Continuing Operations growth was 29%. The average annual Income from Continuing Operations growth rates for Cyclopharm Ltd have been 8% over the past three years , -166% over the past five years , and 7% over the past ten years .